Revisiting dosing regimen using PK/PD modeling: the MODEL1 phase I/II trial of docetaxel plus epirubicin in metastatic breast cancer patients
Crossref DOI link: https://doi.org/10.1007/s10549-016-3760-9
Published Online: 2016-03-22
Published Print: 2016-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Hénin, Emilie
Meille, Christophe
Barbolosi, Dominique
You, Benoit
Guitton, Jérôme
Iliadis, Athanassios
Freyer, Gilles
Text and Data Mining valid from 2016-03-22